The Clorox Company $CLX Shares Sold by L. Roy Papp & Associates LLP

by · The Cerbat Gem

L. Roy Papp & Associates LLP trimmed its stake in The Clorox Company (NYSE:CLX – Free Report) by 9.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,981 shares of the company’s stock after selling 1,453 shares during the quarter. L. Roy Papp & Associates LLP’s holdings in Clorox were worth $1,679,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Hsbc Holdings PLC boosted its position in shares of Clorox by 118.8% in the first quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock worth $159,699,000 after buying an additional 589,544 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in shares of Clorox by 101.8% in the second quarter. Robeco Institutional Asset Management B.V. now owns 1,083,723 shares of the company’s stock worth $130,123,000 after buying an additional 546,761 shares during the period. KBC Group NV boosted its position in shares of Clorox by 688.7% in the first quarter. KBC Group NV now owns 587,679 shares of the company’s stock worth $86,535,000 after buying an additional 513,171 shares during the period. AQR Capital Management LLC boosted its position in shares of Clorox by 412.1% in the first quarter. AQR Capital Management LLC now owns 598,758 shares of the company’s stock worth $88,167,000 after buying an additional 481,846 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Clorox by 147.6% in the first quarter. Goldman Sachs Group Inc. now owns 707,005 shares of the company’s stock worth $104,107,000 after buying an additional 421,453 shares during the period. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the transaction, the chief operating officer directly owned 54,221 shares in the company, valued at $6,711,475.38. The trade was a 21.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.57% of the stock is owned by corporate insiders.

Clorox Trading Up 0.3%

Clorox stock opened at $119.98 on Friday. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. The business’s 50-day simple moving average is $122.27 and its 200-day simple moving average is $128.94. The firm has a market capitalization of $14.67 billion, a PE ratio of 18.40, a PEG ratio of 0.98 and a beta of 0.52. The Clorox Company has a 52 week low of $116.53 and a 52 week high of $171.37.

Clorox (NYSE:CLX – Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.24 by $0.63. The business had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Equities research analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 4.1%. The ex-dividend date is Wednesday, October 22nd. Clorox’s payout ratio is currently 76.07%.

Analyst Ratings Changes

Several analysts have recently commented on the company. The Goldman Sachs Group decreased their target price on Clorox from $115.00 to $110.00 and set a “sell” rating for the company in a research report on Wednesday, October 1st. Barclays decreased their target price on Clorox from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Tuesday, September 30th. Citigroup decreased their target price on Clorox from $135.00 to $130.00 and set a “neutral” rating for the company in a research report on Wednesday. Bank of America decreased their target price on Clorox from $135.00 to $125.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Wells Fargo & Company reduced their price objective on Clorox from $130.00 to $125.00 and set an “equal weight” rating for the company in a research report on Thursday, September 25th. One investment analyst has rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $132.54.

Check Out Our Latest Stock Report on CLX

About Clorox

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Featured Stories